• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: implications for Parkinson's disease.通过 c-Abl 介导的酪氨酸磷酸化调控 parkin 功能:对帕金森病的影响。
J Neurosci. 2011 Jan 5;31(1):157-63. doi: 10.1523/JNEUROSCI.1833-10.2011.
2
Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function.c-Abl 蛋白酪氨酸激酶的磷酸化抑制了 parkin 的泛素化及其保护功能。
Proc Natl Acad Sci U S A. 2010 Sep 21;107(38):16691-6. doi: 10.1073/pnas.1006083107. Epub 2010 Sep 7.
3
Neuroprotective efficacy of a new brain-penetrating C-Abl inhibitor in a murine Parkinson's disease model.新型穿透血脑屏障的 C-Abl 抑制剂在帕金森病小鼠模型中的神经保护作用。
PLoS One. 2013 May 31;8(5):e65129. doi: 10.1371/journal.pone.0065129. Print 2013.
4
The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease.c-Abl 抑制剂尼罗替尼可保护帕金森病动物模型中的多巴胺能神经元。
Sci Rep. 2014 May 2;4:4874. doi: 10.1038/srep04874.
5
Parkin-mediated protection of dopaminergic neurons in a chronic MPTP-minipump mouse model of Parkinson disease.Parkin 介导的慢性 MPTP 微泵小鼠帕金森病模型中多巴胺能神经元的保护作用。
J Neuropathol Exp Neurol. 2011 Aug;70(8):686-97. doi: 10.1097/NEN.0b013e3182269ecd.
6
STEP61 is a substrate of the E3 ligase parkin and is upregulated in Parkinson's disease.STEP61是E3泛素连接酶帕金的底物,在帕金森病中上调。
Proc Natl Acad Sci U S A. 2015 Jan 27;112(4):1202-7. doi: 10.1073/pnas.1417423112. Epub 2015 Jan 12.
7
Dyrk1A phosphorylates parkin at Ser-131 and negatively regulates its ubiquitin E3 ligase activity.酪蛋白激酶1A(Dyrk1A)使帕金蛋白(parkin)的丝氨酸131位点磷酸化,并对其泛素E3连接酶活性起负调控作用。
J Neurochem. 2015 Aug;134(4):756-68. doi: 10.1111/jnc.13164. Epub 2015 Jun 3.
8
Teaghrelin protected dopaminergic neurons in MPTP-induced Parkinson's disease animal model by promoting PINK1/Parkin-mediated mitophagy and AMPK/SIRT1/PGC1-α-mediated mitochondrial biogenesis.Teaghrelin 通过促进 PINK1/Parkin 介导的线粒体自噬和 AMPK/SIRT1/PGC1-α 介导的线粒体生物发生来保护 MPTP 诱导的帕金森病动物模型中的多巴胺能神经元。
Environ Toxicol. 2024 Jul;39(7):4022-4034. doi: 10.1002/tox.24275. Epub 2024 Apr 15.
9
Parkin interacting substrate phosphorylation by c-Abl drives dopaminergic neurodegeneration.Parkin 与 c-Abl 的相互作用底物磷酸化驱动多巴胺能神经元退行性变。
Brain. 2021 Dec 31;144(12):3674-3691. doi: 10.1093/brain/awab356.
10
Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death.真正的帕金森蛋白底物氨酰-tRNA合成酶辅因子p38/JTV-1的积累会导致儿茶酚胺能细胞死亡。
J Neurosci. 2005 Aug 31;25(35):7968-78. doi: 10.1523/JNEUROSCI.2172-05.2005.

引用本文的文献

1
Differential role of C-terminal truncations on alpha-synuclein pathology and Lewy body formation.α-突触核蛋白C末端截短在病理学及路易小体形成中的不同作用
NPJ Parkinsons Dis. 2025 Aug 26;11(1):261. doi: 10.1038/s41531-025-01084-y.
2
Experimental and clinical tests of FDA-approved kinase inhibitors for the treatment of neurological disorders (update 2024).美国食品药品监督管理局(FDA)批准的用于治疗神经疾病的激酶抑制剂的实验和临床测试(2024年更新)
Explor Drug Sci. 2025;3. doi: 10.37349/eds.2025.1008116. Epub 2025 Jul 1.
3
c-Abl Inhibitors in Parkinson's: Exploring Hypotheses on Alpha-Synuclein Modulation.帕金森病中的c-Abl抑制剂:探索α-突触核蛋白调节假说
Adv Pharm Bull. 2025 Feb 9;15(1):7-10. doi: 10.34172/apb.42806. eCollection 2025 Apr.
4
Formation of seeding-competent α-synuclein aggregates in parkin-deficient iPSC-derived human neurons.在缺乏parkin的诱导多能干细胞衍生的人类神经元中形成具有种子形成能力的α-突触核蛋白聚集体。
NPJ Parkinsons Dis. 2025 Jun 21;11(1):180. doi: 10.1038/s41531-025-01038-4.
5
Molecular mechanisms and consequences of TDP-43 phosphorylation in neurodegeneration.神经退行性变中TDP - 43磷酸化的分子机制及后果
Mol Neurodegener. 2025 May 8;20(1):53. doi: 10.1186/s13024-025-00839-8.
6
Neuroprotective role and mechanistic insights of DJ-1 dimerization in Parkinson's disease.DJ-1二聚化在帕金森病中的神经保护作用及机制洞察
Cell Commun Signal. 2025 Mar 10;23(1):129. doi: 10.1186/s12964-025-02136-9.
7
Preclinical studies and transcriptome analysis in a model of Parkinson's disease with dopaminergic ZNF746 expression.在具有多巴胺能ZNF746表达的帕金森病模型中的临床前研究和转录组分析。
Mol Neurodegener. 2025 Feb 28;20(1):24. doi: 10.1186/s13024-025-00814-3.
8
Novel Electrochemical Approaches for Anticancer Drug Monitoring: Application of CoS@Nitrogen-Doped Amorphous Porous Carbon Composite in Nilotinib Detection.用于抗癌药物监测的新型电化学方法:CoS@氮掺杂非晶态多孔碳复合材料在尼洛替尼检测中的应用。
ACS Omega. 2024 Dec 31;10(1):261-271. doi: 10.1021/acsomega.4c05505. eCollection 2025 Jan 14.
9
α-Synuclein pathology as a target in neurodegenerative diseases.α-突触核蛋白病变作为神经退行性疾病的一个靶点。
Nat Rev Neurol. 2025 Jan;21(1):32-47. doi: 10.1038/s41582-024-01043-w. Epub 2024 Nov 28.
10
AIMP2 accumulation in brain leads to cognitive deficits and blood secretion in Parkinson's disease.AIMP2 在大脑中的积累导致帕金森病中的认知缺陷和血液分泌。
J Transl Med. 2024 Oct 10;22(1):919. doi: 10.1186/s12967-024-05666-x.

本文引用的文献

1
MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity.小鼠黑质和蓝斑去甲肾上腺素能神经元对MPTP和DSP-4的易感性与帕金蛋白活性无关。
Neurobiol Dis. 2007 May;26(2):312-22. doi: 10.1016/j.nbd.2006.12.021. Epub 2007 Jan 25.
2
Identification of far upstream element-binding protein-1 as an authentic Parkin substrate.鉴定远上游元件结合蛋白-1为真正的帕金底物。
J Biol Chem. 2006 Jun 16;281(24):16193-6. doi: 10.1074/jbc.C600041200. Epub 2006 May 3.
3
Diverse effects of pathogenic mutations of Parkin that catalyze multiple monoubiquitylation in vitro.在体外催化多个单泛素化的帕金蛋白致病突变的多种效应。
J Biol Chem. 2006 Feb 10;281(6):3204-9. doi: 10.1074/jbc.M510393200. Epub 2005 Dec 8.
4
Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function.应激诱导的帕金蛋白溶解性改变促进帕金蛋白聚集并损害其保护功能。
Hum Mol Genet. 2005 Dec 15;14(24):3885-97. doi: 10.1093/hmg/ddi413. Epub 2005 Nov 8.
5
Dopamine covalently modifies and functionally inactivates parkin.多巴胺可共价修饰并使帕金蛋白功能失活。
Nat Med. 2005 Nov;11(11):1214-21. doi: 10.1038/nm1314. Epub 2005 Oct 16.
6
Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death.真正的帕金森蛋白底物氨酰-tRNA合成酶辅因子p38/JTV-1的积累会导致儿茶酚胺能细胞死亡。
J Neurosci. 2005 Aug 31;25(35):7968-78. doi: 10.1523/JNEUROSCI.2172-05.2005.
7
Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin.家族性相关突变以不同方式破坏帕金森蛋白的溶解性、定位、结合和泛素化特性。
Hum Mol Genet. 2005 Sep 1;14(17):2571-86. doi: 10.1093/hmg/ddi292. Epub 2005 Jul 27.
8
Molecular pathophysiology of Parkinson's disease.帕金森病的分子病理生理学
Annu Rev Neurosci. 2005;28:57-87. doi: 10.1146/annurev.neuro.28.061604.135718.
9
The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.乳腺癌耐药蛋白1(ABCG2)对甲磺酸伊马替尼(格列卫)体内药代动力学及脑渗透的影响:乳腺癌耐药蛋白及P-糖蛋白抑制剂用于使伊马替尼在患者中实现脑渗透的意义。
Cancer Res. 2005 Apr 1;65(7):2577-82. doi: 10.1158/0008-5472.CAN-04-2416.
10
Parkin phosphorylation and modulation of its E3 ubiquitin ligase activity.帕金蛋白的磷酸化及其E3泛素连接酶活性的调节
J Biol Chem. 2005 Feb 4;280(5):3390-9. doi: 10.1074/jbc.M407724200. Epub 2004 Nov 22.

通过 c-Abl 介导的酪氨酸磷酸化调控 parkin 功能:对帕金森病的影响。

Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: implications for Parkinson's disease.

机构信息

Department of Medicine, University of Texas Health Science Center, San Antonio, Texas 78229, USA.

出版信息

J Neurosci. 2011 Jan 5;31(1):157-63. doi: 10.1523/JNEUROSCI.1833-10.2011.

DOI:10.1523/JNEUROSCI.1833-10.2011
PMID:21209200
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3039694/
Abstract

Mutations in parkin, an E3 ubiquitin ligase, are the most common cause of autosomal-recessive Parkinson's disease (PD). Here, we show that the stress-signaling non-receptor tyrosine kinase c-Abl links parkin to sporadic forms of PD via tyrosine phosphorylation. Under oxidative and dopaminergic stress, c-Abl was activated in cultured neuronal cells and in striatum of adult C57BL/6 mice. Activated c-Abl was found in the striatum of PD patients. Concomitantly, parkin was tyrosine-phosphorylated, causing loss of its ubiquitin ligase and cytoprotective activities, and the accumulation of parkin substrates, AIMP2 (aminoacyl tRNA synthetase complex-interacting multifunctional protein 2) (p38/JTV-1) and FBP-1.STI-571, a selective c-Abl inhibitor, prevented tyrosine phosphorylation of parkin and restored its E3 ligase activity and cytoprotective function both in vitro and in vivo. Our results suggest that tyrosine phosphorylation of parkin by c-Abl is a major post-translational modification that leads to loss of parkin function and disease progression in sporadic PD. Moreover, inhibition of c-Abl offers new therapeutic opportunities for blocking PD progression.

摘要

Parkin 是一种 E3 泛素连接酶,其突变是常染色体隐性遗传帕金森病(PD)最常见的原因。在这里,我们发现应激信号非受体酪氨酸激酶 c-Abl 通过酪氨酸磷酸化将 parkin 与散发性 PD 联系起来。在氧化和多巴胺能应激下,c-Abl 在培养的神经元细胞和成年 C57BL/6 小鼠的纹状体中被激活。PD 患者的纹状体中发现了活化的 c-Abl。同时,parkin 发生酪氨酸磷酸化,导致其失去泛素连接酶和细胞保护活性,并积累 parkin 底物,AIMP2(氨基酰 tRNA 合成酶复合物相互作用多功能蛋白 2)(p38/JTV-1)和 FBP-1。STI-571 是一种选择性 c-Abl 抑制剂,可防止 parkin 的酪氨酸磷酸化,并在体外和体内恢复其 E3 连接酶活性和细胞保护功能。我们的研究结果表明,c-Abl 对 parkin 的酪氨酸磷酸化是导致散发性 PD 中 parkin 功能丧失和疾病进展的主要翻译后修饰。此外,抑制 c-Abl 为阻止 PD 进展提供了新的治疗机会。